Weekly Recap | TEVA.US +5.1%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Teva (TEVA) gained 5.1% this week to close at $38.98, outperforming the S&P 500 by roughly 5.18 percentage points. The week was choppy but upward-leaning: Monday opened near $37.66 and dipped to $37.00 before recovering to $38.72, Tuesday pushed toward $39.49 on higher volume, Thursday printed the weekly high at $39.70, and Friday edged back to $38.98. Price stayed above the 20-day moving average at $37.44 for the whole week, with the 60-day line at $35.10 further down.
The Week
Teva (TEVA) gained 5.1% this week to close at $38.98, outperforming the S&P 500 by roughly 5.18 percentage points. The week was choppy but upward-leaning: Monday opened near $37.66 and dipped to $37.00 before recovering to $38.72, Tuesday pushed toward $39.49 on higher volume, Thursday printed the weekly high at $39.70, and Friday edged back to $38.98. Price stayed above the 20-day moving average at $37.44 for the whole week, with the 60-day line at $35.10 further down. Weekly amplitude came to 7.17%, and average daily volume of 54.7m shares ran about 13% above the median.
Key Events
The week’s main thread was Teva’s switch from American Depositary Shares (ADS) to direct ordinary share trading on the NYSE. The company framed the move on Monday as a milestone in its pivot to a growth strategy, and the shares repeatedly tested the $39 handle in the days after direct trading began. Teva also said growth in branded drugs and biosimilars is accelerating. On Thursday, Teva Pharmaceutical Finance Netherlands II issued EUR 1bn of 4.250% senior notes due 2033. After Friday’s close, the company released schizophrenia long-acting injectable data: post hoc analyses for olanzapine LAI TEV-749 showed high stabilisation rates and long-term efficacy, while real-world data for UZEDY (risperidone) showed better treatment retention than other long-acting injectables, along with lower emergency care and healthcare costs.
Analyst Ratings
Among the 3 firms covering Teva, 1 rates it buy, 1 rates it over, and 1 has no opinion; none rate it hold, under or sell. The consensus rating is buy, with a consensus target price of $42, about 7.75% above the current price of $38.98. The target range is tight, with both high and low at $42. Within its industry, Teva ranks 136th out of 204 names, in the middle-lower band.
The Week Ahead
Teva has no earnings or company-specific events on next week’s calendar, but macro data may set the tone for overall market sentiment: the Richmond Fed composite on Tuesday, EIA crude inventories on Wednesday, and initial jobless claims plus new home sales on Thursday. On the company side, the key catalyst is the US FDA approval decision for olanzapine LAI TEV-749, due in Q4 2026.
In Short
This week’s share price gain sat alongside the NYSE listing shift, a EUR 1bn debt raise and fresh long-acting injectable data in the same stretch. The latest daily money-flow snapshot shows large-lot money on the sell side while small- and medium-lot flows turn net buyers, a typical retail-absorbs-institutional-sales pattern. The consensus rating is buy with a target about 7.75% above spot, but valuation sits at roughly 64x P/E and 5.86x P/B on the latest snapshot, which is not cheap. The open question is whether the Q4 FDA decision for TEV-749 lands cleanly and whether branded drugs and biosimilars can deliver the accelerated growth now being priced in.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.